AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3285535 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (Aza)
Number of subjects: 108
Study 29396738 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic-guided warfarin arm (GEN)
Number of subjects: 180
Study 29396738 — intervention group
Group type: COMPARATOR
Intervention: Control arm (CTL)
Number of subjects: 180
Study 26603056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg twice daily plus Best Supportive Care (BSC)
Number of subjects: 764
Study 26603056 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Best Supportive Care (BSC)
Number of subjects: 764
Study 23720394 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI method for quantifying hepatic storage iron
Number of subjects: 26
Study 24304838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-alone group
Number of subjects: 993
Study 24304838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-plus-support group
Number of subjects: 993
Study 24304838 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 993
Study 24304838 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 993
Study 24304838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness assessment
Number of subjects: 993
Study 20552099 — intervention group
Group type: COMPARATOR
Intervention: GIC (Ketac-Cem)
Number of subjects: 60
Study 20552099 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP-containing orthodontic cement (Aegis-Ortho)
Number of subjects: 60
Study 20552099 — intervention group
Group type: COMPARATOR
Intervention: GIC (Ketac-Cem) and ACP-containing cement (Aegis-Ortho)
Number of subjects: 60
Study 19087842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 6000
Study 15850127 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor-monitoring algorithm using LifeShirt system
Number of subjects: 0
Study 15850127 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study 11880087 — intervention group
Group type: EXPERIMENTAL
Intervention: Water load
Number of subjects: 72
Study 11880087 — intervention group
Group type: COMPARATOR
Intervention: No water load
Number of subjects: 72
Study 10069783 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae IgG titers >/=1:16
Number of subjects: 343
Study 10069783 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae IgG titers 1:32
Number of subjects: 343
Study 10069783 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae IgG titers 1:64
Number of subjects: 343
Study 10069783 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae IgG titers 1:128
Number of subjects: 343
Study 10069783 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae IgG titers 1:256
Number of subjects: 343
Study 10069783 — intervention group
Group type: COMPARATOR
Intervention: Chlamydia pneumoniae IgG seropositivity
Number of subjects: 343
Study 10069783 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein concentration
Number of subjects: 343
Study 7584746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (ALB) 2.5 mg
Number of subjects: 83
Study 7584746 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (TERB) 0.25 mg
Number of subjects: 83
Study 7584746 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline injection)
Number of subjects: 83
Study 2300680 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (100, 200, and 300 mg)
Number of subjects: 8
Study 2300680 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl (10 mg)
Number of subjects: 8
Study 2300680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6932207 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg PG F2α
Number of subjects: 90
Study 6932207 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg PG F2α
Number of subjects: 90
Study 6932207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 6932207 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined prostaglandin-treated group (25 mg and 50 mg PG F2α)
Number of subjects: 90
Study 30616650 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about availability of adolescent and youth friendly sexual and reproductive health services at health facilities
Number of subjects: 144
Study 30616650 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilization of adolescent and youth friendly sexual and reproductive health services
Number of subjects: 144
Study 30616650 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational status: being grade 9
Number of subjects: 144
Study 30616650 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational status: being grade 11
Number of subjects: 144
Study 27568072 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (800mg calcium and 400IU vitamin D daily, n=8)
Number of subjects: 17
Study 27568072 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=9)
Number of subjects: 17
Study 26525550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery combined with Chinese medicine treatment
Number of subjects: 72
Study 26525550 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 72
Study 23351578 — intervention group
Group type: EXPERIMENTAL
Intervention: Wax-matrix extended-release niacin (WMER) 1500 mg/d
Number of subjects: 120
Study 23351578 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol hexanicotinate (IHN) 1500 mg/d
Number of subjects: 120
Study 23351578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 21327538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 0
Study 21327538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 0
Study 21327538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18801639 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help treatment (book and 6 weeks of DVD or videotape)
Number of subjects: 247
Study 18801639 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 247
Study 17439514 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydimethylsiloxane elastomer
Number of subjects: 44
Study 17439514 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 44
Study 14671645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated rIFN-alpha2b (6 microg/kg/week)
Number of subjects: 344
Study 14671645 — intervention group
Group type: COMPARATOR
Intervention: rIFN-alpha2b (5 million International Units/m2/day)
Number of subjects: 344
Study 14671645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated rIFN-alpha2b (6 microg/kg/week) among patients with HCT >33%
Number of subjects: 344
Study 14671645 — intervention group
Group type: COMPARATOR
Intervention: rIFN-alpha2b (5 million International Units/m2/day) among patients with HCT >33%
Number of subjects: 344
Study 11403176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg three times per day starting the day before radiation therapy)
Number of subjects: 49
Study 11403176 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy without pilocarpine (Control group)
Number of subjects: 49
Study 10888995 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot dissection tonsillectomy
Number of subjects: 54
Study 10888995 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 54
Study 8933126 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of raw ginger root daily for two weeks
Number of subjects: 18
Study 8933126 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g of cooked stem ginger daily for two weeks
Number of subjects: 18
Study 8933126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1579513 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunofluorescent method (IFL)
Number of subjects: 16
Study 1579513 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-ELISA method
Number of subjects: 16
Study 1579513 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IFL and ELISA methods
Number of subjects: 16
Study 4064546 — intervention group
Group type: EXPERIMENTAL
Intervention: 50.0 Gy in 20 daily fractions
Number of subjects: 94
Study 4064546 — intervention group
Group type: EXPERIMENTAL
Intervention: 52.5 Gy in 20 daily fractions
Number of subjects: 94
Study 4064546 — intervention group
Group type: EXPERIMENTAL
Intervention: 57.5 Gy in 20 daily fractions
Number of subjects: 94
Study 30032505 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml 12.5% CHO
Number of subjects: 100
Study 30032505 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml 12.5% CHO
Number of subjects: 100
Study 30032505 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ml 12.5% CHO
Number of subjects: 100
Study 30032505 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml 12.5% CHO
Number of subjects: 100
Study 26325531 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-site ventricular stimulation (TRIV)
Number of subjects: 76
Study 26325531 — intervention group
Group type: COMPARATOR
Intervention: Conventional CRT
Number of subjects: 76
Study 26325531 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIV
Number of subjects: 76
Study 24332514 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronic acid 50 mg daily
Number of subjects: 705
Study 24332514 — intervention group
Group type: COMPARATOR
Intervention: Intravenous zoledronic acid 4 mg every 3-4 weeks
Number of subjects: 705
Study 22290638 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis-mixed psychoeducational (PE)
Number of subjects: 82
Study 22290638 — intervention group
Group type: COMPARATOR
Intervention: Non-specific intervention control group
Number of subjects: 82
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem (MA) with silica coating
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartcem (SM) with silica coating
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely X Unicem Aplicap (UN) with silica coating
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Breeze (BR) with silica coating
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscem (BI) with silica coating
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Set (SE) with silica coating
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SA luting (CL) with silica coating
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem (MA) with tribochemical treatment
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartcem (SM) with tribochemical treatment
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely X Unicem Aplicap (UN) with tribochemical treatment
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Breeze (BR) with tribochemical treatment
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscem (BI) with tribochemical treatment
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Set (SE) with tribochemical treatment
Number of subjects: 0
Study 20690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SA luting (CL) with tribochemical treatment
Number of subjects: 0
Study 20690416 — intervention group
Group type: COMPARATOR
Intervention: #600 polishing (control group)
Number of subjects: 0
Study 17505991 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful eradication of H. pylori
Number of subjects: 333
Study 17505991 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of the index ulcer (<=10 mm versus >10 mm)
Number of subjects: 333
Study 17505991 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrophic gastritis versus no atrophy
Number of subjects: 333
Study 16182353 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine (0, 2.5, 5, 10 and 15 mg) alone
Number of subjects: 6
Study 16182353 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (20 mg)
Number of subjects: 6
Study 16182353 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam (20 mg) + d-Amphetamine (15 mg)
Number of subjects: 6
Study 12106937 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 4054
Study 10093841 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast FLAIR imaging
Number of subjects: 47
Study 7475282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine treatment
Number of subjects: 31
Study 7475282 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 31
Study 7475282 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 31
Study 2278365 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate in lipid emulsion (20 mg in 10 ml of Lipofundin MCT 20%)
Number of subjects: 100
Study 2278365 — intervention group
Group type: COMPARATOR
Intervention: Etomidate in propylene glycol (35% solution)
Number of subjects: 100
Study 31553204 — intervention group
Group type: EXPERIMENTAL
Intervention: MgBRS
Number of subjects: 150
Study 31553204 — intervention group
Group type: COMPARATOR
Intervention: SES
Number of subjects: 150
Study 30256569 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behavior modification program
Number of subjects: 66
Study 30256569 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 66
Study 26883307 — intervention group
Group type: EXPERIMENTAL
Intervention: Community leader engagement
Number of subjects: 45
Study 26883307 — intervention group
Group type: EXPERIMENTAL
Intervention: Community leader engagement with community days
Number of subjects: 45
Study 26883307 — intervention group
Group type: EXPERIMENTAL
Intervention: Community leader engagement with community days and male and female community peer groups
Number of subjects: 45
Study 24792208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical loading at 50% body weight
Number of subjects: 137
Study 23096013 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil (SO)
Number of subjects: 18
Study 23096013 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-SFA soybean oil (LoSFA-SO)
Number of subjects: 18
Study 23096013 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic acid soybean oil (HiOleic-SO)
Number of subjects: 18
Study 23096013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogenated soybean oil (Hydrog-SO)
Number of subjects: 18
Study 23096013 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-ALA soybean oil (LoALA-SO)
Number of subjects: 18
Study 20170026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer screening using the Pap test
Number of subjects: 0
Study 20170026 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 125 test for detecting relapse in ovarian cancer
Number of subjects: 0
Study 20170026 — intervention group
Group type: COMPARATOR
Intervention: Initiation of therapy for ovarian cancer
Number of subjects: 0
Study 20170026 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised staging for cervical, endometrial, and vulvar cancer by FIGO
Number of subjects: 0
Study 17710561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist recommendations for drug therapy changes (267 recommendations total)
Number of subjects: 101
Study 17710561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist recommendations to add a new antihypertensive medication (46.4%) or increase a dose (33.3%)
Number of subjects: 101
Study 17710561 — intervention group
Group type: EXPERIMENTAL
Intervention: Average blood pressure at baseline: 153.1±10.0/84.9±12.0 mmHg
Number of subjects: 101
Study 17710561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist recommendations for no change in treatment plan (361 times)
Number of subjects: 101
Study 17710561 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall BP control rates
Number of subjects: 101
Study 15877552 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized video vignettes of an elderly patient depicting late-life depression
Number of subjects: 178
Study 15877552 — intervention group
Group type: EXPERIMENTAL
Intervention: PCP characteristics (location of medical school training)
Number of subjects: 178
Study 12607119 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral varicose vein surgery
Number of subjects: 73
Study 12607119 — intervention group
Group type: COMPARATOR
Intervention: Bilateral varicose vein surgery
Number of subjects: 73
Study 10388959 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 375
Study 10388959 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.05% gel
Number of subjects: 375
Study 10388959 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 375
Study 8697168 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI pacing
Number of subjects: 20
Study 8697168 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 20
Study 1997933 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (3 mg/kg, 15 min i.v.)
Number of subjects: 36
Study 1997933 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg slow push)
Number of subjects: 36
Study 6359995 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 29
Study 6359995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30898462 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-based approach
Number of subjects: 140
Study 30898462 — intervention group
Group type: COMPARATOR
Intervention: Physician choice of antibiotic
Number of subjects: 140
Study 30898462 — intervention group
Group type: COMPARATOR
Intervention: Prebiopsy cultures
Number of subjects: 140
Study 29871025 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment
Number of subjects: 133
Study 29871025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 27291558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar TURBT (B‐TURBT)
Number of subjects: 130
Study 27291558 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURBT (M‐TURBT)
Number of subjects: 130
Study 25085298 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser treatment (beam diameter, 0.2 mm; power, 0.7 W)
Number of subjects: 16
Study 25085298 — intervention group
Group type: COMPARATOR
Intervention: Visible guiding light (control)
Number of subjects: 16
Study 22147075 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib (45 mg) plus Dextromethorphan (DM)
Number of subjects: 14
Study 18852068 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 107
Study 17382026 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus EGFR tyrosine kinase inhibitors (gefitinib or erlotinib)
Number of subjects: 4000
Study 17382026 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 4000
Study 15105062 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic combined oral contraceptive (COC)
Number of subjects: 29
Study 15105062 — intervention group
Group type: COMPARATOR
Intervention: Control group of 49 non-COC-user women
Number of subjects: 29
Study 12192203 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions discussed in literature (specific interventions not detailed in the abstract)
Number of subjects: 0
Study 12192203 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential future therapies and prophylactic recommendations
Number of subjects: 0
Study 11579697 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 0
Study 11579697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock music
Number of subjects: 0
Study 11579697 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise
Number of subjects: 0
Study 11579697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock music and noise
Number of subjects: 0
Study 8130022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 33
Study 8130022 — intervention group
Group type: EXPERIMENTAL
Intervention: Metolazone
Number of subjects: 33
Study 8130022 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Bendrofluazide + Loop diuretic)
Number of subjects: 33
Study 8130022 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged treatment (Bendrofluazide + Loop diuretic)
Number of subjects: 33
Study 8130022 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Bendrofluazide + Metolazone + Loop diuretic)
Number of subjects: 33
Study 2502921 — intervention group
Group type: EXPERIMENTAL
Intervention: EN‐8715 (8% soluble fiber, 18% Polycose, 7% fructose, 50% fat, 17% protein)
Number of subjects: 10
Study 2502921 — intervention group
Group type: COMPARATOR
Intervention: Ensure HN (53% simple carbohydrates, 30% fat, 17% protein)
Number of subjects: 10
Study 2502921 — intervention group
Group type: EXPERIMENTAL
Intervention: EN‐8715
Number of subjects: 10
Study 2502921 — intervention group
Group type: COMPARATOR
Intervention: Ensure HN
Number of subjects: 10
Study 29973165 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Health Management (IHM) lifestyle program, including access to a web-based health portal and participation in training sessions (3 full-day and 10 two-hour sessions in the first 3 months, followed by 4 training sessions and weekly monitoring for 9 months).
Number of subjects: 0
Study 29973165 — intervention group
Group type: COMPARATOR
Intervention: Control group with access to the IHM program after a waiting period of at least 6 months.
Number of subjects: 0
Study 29973165 — intervention group
Group type: EXPERIMENTAL
Intervention: IHM program includes examinations for burnout symptoms, heart rate variability, laboratory and physical findings, and patient-reported outcomes such as well-being, life satisfaction, severity of mood state, sense of coherence, psycho-vegetative test, cardio-metabolic risk factors, hypertension, and diabetes risk.
Number of subjects: 0
Study 29211279 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine pre‐procedural rinse
Number of subjects: 54